Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.
COVID-19
Convalescent donor
Half-life
Neutralising antibodies
SARS-CoV-2
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
05
07
2021
revised:
30
09
2021
accepted:
01
10
2021
pubmed:
8
10
2021
medline:
1
12
2021
entrez:
7
10
2021
Statut:
ppublish
Résumé
Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutralisation assays and employed them to examine the half-life of SARS-CoV-2 neutralising antibodies in convalescent plasma donations made by 42 repeat donors between April and September 2020. SARS-CoV-2 neutralising antibody titres decreased over time but typically remained above the methods' diagnostic cut-offs. Using this longitudinal data, the average half-life of SARS-CoV-2 neutralising antibodies was determined to be 20.4 days. SARS-CoV-2 neutralising antibody titres appear to persist in the majority of donors for several months. Whether these titres confer protection against re-infection requires further study and is of particular relevance as COVID-19 vaccines become widely available.
Identifiants
pubmed: 34619377
pii: S1521-6616(21)00208-4
doi: 10.1016/j.clim.2021.108871
pmc: PMC8489294
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108871Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Respirology. 2006 Jan;11(1):49-53
pubmed: 16423201
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Clin Immunol. 2007 Feb;122(2):146-55
pubmed: 17046328
Med. 2021 Mar 12;2(3):281-295.e4
pubmed: 33589885
N Engl J Med. 2007 Sep 13;357(11):1162-3
pubmed: 17855683
Lancet. 2021 Mar 20;397(10279):1075-1084
pubmed: 33743869
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Biosens Bioelectron. 2021 Jan 15;172:112752
pubmed: 33126180
Nat Commun. 2021 Jan 4;12(1):63
pubmed: 33397909
Transbound Emerg Dis. 2022 May;69(3):1596-1605
pubmed: 33960696
Clin Infect Dis. 2021 Sep 15;73(6):e1337-e1344
pubmed: 33851216
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Scand J Infect Dis. 2011 Jul;43(6-7):515-21
pubmed: 21366405
J Pharm Sci. 2004 Nov;93(11):2645-68
pubmed: 15389672
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Nat Commun. 2021 May 11;12(1):2670
pubmed: 33976165
EClinicalMedicine. 2021 Feb;32:100734
pubmed: 33589882
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Infect Dis. 2021 Sep 1;224(5):754-763
pubmed: 34467985
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
Cell Host Microbe. 2021 Jun 9;29(6):917-929.e4
pubmed: 33984285